Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;50(1):24-9.
doi: 10.1016/j.cyto.2009.12.002. Epub 2010 Feb 1.

Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in healthy vaccinees

Affiliations

Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in healthy vaccinees

Neelam Dhiman et al. Cytokine. 2010 Apr.

Abstract

We conducted a population-based study on 738 schoolchildren who received two doses of rubella vaccine in order to determine cytokine secretion patterns and their associations with demographic and clinical variables. The results showed a robust rubella-specific inflammatory cytokine response characterized by high median [inter-quartile range (IQR)] secretion levels (in pg/mL) of IL-6 [3681.0 (3160.0, 4052.0)], GM-CSF [28.0 (23.6, 32.6)], and TNF-alpha [29.7 (-7.0, 89.2)]. We also detected modest levels of rubella-specific secretion of Th1 cytokines IL-2 and IFN-gamma, while IL-12p40 was undetectable. In contrast, rubella-specific Th2 responses were hardly detectable. Age at vaccination, enrollment, and time elapsed between last vaccination and enrollment was significantly associated with the outcome of IL-2, IL-6, and IFN-gamma secretion. These results suggest an immune-deviation or "skewing" from Th1/Th2 cytokine patterns towards a predominant inflammatory response upon in vitro rubella virus stimulation.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure

Dr. Poland is the chair of a Safety Evaluation Committee for novel non-rubella vaccines undergoing clinical studies by Merck Research Laboratories. Dr. Jacobson serves on a Safety Review Committee for a post-licensure study of a human papillomavirus vaccine for Kaiser-Permanente. Other authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Plotkin SA. Rubella eradication. Vaccine. 2001;19:3311–3319. - PubMed
    1. Mitchell LA, Tingle J, Décarie D, Lajeunesse C. Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR. Can J Public Health. 1998;89:325–328. - PMC - PubMed
    1. Shohat T, Manfred SG, Orly N, Ami B, Poriya D, Avital C, et al. Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Isr Med Assoc J. 2000;2:192–195. - PubMed
    1. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401–409. - PubMed
    1. Skendzel LP. Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol. 1996;106:170–174. - PubMed

Publication types

LinkOut - more resources